JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JVI Accepts, published online ahead of print on 7 November 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.01634-07v1
82/7/3166    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoenly, K. A.
Right arrow Articles by Weiner, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoenly, K. A.
Right arrow Articles by Weiner, D. B.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.01634-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

HIV-1 Vaccine Development: Recent Advances in the CTL Platform "Spotty Business"

Kimberly A. Schoenly and David B. Weiner*

The Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine

* To whom correspondence should be addressed. Email: dbweiner{at}mail.med.upenn.edu.


  Abstract

For human immunodeficiency virus type 1 (HIV-1) vaccine development, a central focus is to develop a vaccine that drives primarily strong and broad CD8+ cytotoxic T lymphocytes (CTLs). ...






Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.